0855 GMT - Sanofi shares fall in European morning trading, while Regeneron Pharmaceuticals is sharply lower in U.S. premarket trading, after the companies reported mixed results from two late-stage trials of a respiratory drug they are jointly developing. Sanofi and Regeneron said drug candidate Itepekimab missed the key goal of a phase 3 trial, but met the primary objective in the other study. Paris-listed shares in Sanofi fall 5.8%, while Regeneron shares drop 12% in U.S. premarket trading. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
May 30, 2025 04:56 ET (08:56 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。